USPTO serial 97255702
180
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- CLARK, ANDREW T
- Law office
- TMEG LAW OFFICE 107 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with 180?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Eric Eisenberg
ERIC EISENBERG AMSTER, ROTHSTEIN & EBENSTEIN LLP90 PARK AVENUENEW YORK, NY 10016UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Analgesic preparations; Pharmaceutical preparations for the treatment of inflammatory diseases; Pharmaceutical preparations for the treatment of inflammation; Pharmaceutical preparations for the treatment of Dupuytren's disease; Pharmaceutical preparations for the treatment of frozen shoulder; Pharmaceutical preparations for the treatment of post-operative delirium; Pharmaceutical preparations for the treatment of post-operative cognitive deficit; Pharmaceutical preparations for the treatment of post-operative cognitive decline; Pharmaceutical preparations for the treatment of non-alcoholic steatohepatitis; Pharmaceutical preparations for the treatment of fibrosis; Pharmaceutical preparations for the treatment of liver fibrosis; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for the treatment of ulcerative colitis; Pharmaceutical preparations for the treatment of anxiety; Pharmaceutical preparations for the treatment of type 1 diabetes; Pharmaceutical preparations for the treatment of type 2 diabetes; Pharmaceutical preparations for inhibition of tumor necrosis factor (TNF); Pharmaceutical preparations for interacting with nicotine receptors; Pharmaceutical preparations for synthetically simulating non-psychoactive effects of cannabidiol (CBD); Pharmaceutical preparations for liver regeneration; Pharmaceutical preparations for regenerative therapy; Pharmaceutical preparations for acting as an alpha-7nAChR agonist | ACTIVE | — |
| 042 | Development of pharmaceutical preparations and medicines; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical research and development; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development in the pharmaceutical and biotechnology fields; Scientific research for medical purposes in the field of inflammatory diseases; Scientific research for medical purposes in the field of treatment of inflammation; Scientific research for medical purposes in the field of Dupuytren's disease; Scientific research for medical purposes in the field of frozen shoulder; Scientific research for medical purposes in the field of post-operative delirium, post-operative cognitive deficit, and post-operative cognitive decline; Scientific research for medical purposes in the field of non-alcoholic steatohepatitis; Scientific research for medical purposes in the field of fibrosis; Scientific research for medical purposes in the field of liver fibrosis; Scientific research for medical purposes in the field of arthritis; Scientific research for medical purposes in the field of pain treatment; Scientific research for medical purposes in the field of ulcerative colitis; Scientific research for medical purposes in the field of treatment of anxiety; Scientific research for medical purposes in the field of inhibition of tumor necrosis factor (TNF) and anti-TNF pharmaceuticals; Scientific research for medical purposes in the field of interactions with nicotine receptors; Scientific research for medical purposes in the field of synthetic simulation of non-psychoactive effects of cannabidiol (CBD); Scientific research for medical purposes in the field of synthetic cannabidiol (CBD) analogs; Scientific research for medical purposes in the field of type 1 diabetes; Scientific research for medical purposes in the field of type 2 diabetes; Scientific research for medical purposes in the field of liver regeneration; Scientific research for medical purposes in the field of regenerative therapy; Scientific research for medical purposes in the field of alpha-7nAChR agonists | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 27, 2024 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jun 27, 2024 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jan 25, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 25, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 25, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 17, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 6, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 4, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 18, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 12, 2022 | MDSM | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Feb 11, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 10, 2022 | NWAP | NEW APPLICATION ENTERED | — |